- Ocrelizumab showed superiority to interferon beta-1a (Rebif®) in two identical Phase III studies in people with relapsing multiple sclerosis (MS), the most common form of the disease
- Ocrelizumab is the first investigational medicine to show efficacy in people with primary progressive MS in a large Phase III study
- Ocrelizumab Phase III data will be presented at the 31st congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 7-10 in Barcelona, Spain
Genentech, a member of the Roche group, today announced data
from three positive, pivotal Phase III studies of ocrelizumab in people with
relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis
(PPMS). Data from two identical studies (called OPERA I and OPERA II) in people
with relapsing MS, which affects approximately 85 percent of people with MS at
the time of diagnosis, showed ocrelizumab was superior to interferon beta-1a
(Rebif®), a well-established MS therapy, in reducing the three major markers of
disease activity over the two-year controlled treatment period.
from three positive, pivotal Phase III studies of ocrelizumab in people with
relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis
(PPMS). Data from two identical studies (called OPERA I and OPERA II) in people
with relapsing MS, which affects approximately 85 percent of people with MS at
the time of diagnosis, showed ocrelizumab was superior to interferon beta-1a
(Rebif®), a well-established MS therapy, in reducing the three major markers of
disease activity over the two-year controlled treatment period.
In a separate study (called ORATORIO) in people with PPMS, a form of the
disease marked by steadily worsening symptoms and typically without distinct
relapses or periods of remission, ocrelizumab significantly reduced the
progression of clinical disability sustained for at least 12 weeks (the primary
endpoint) and 24 weeks (a secondary endpoint) compared with placebo.
Additionally, the study met other secondary endpoints of reducing the time
required to walk 25 feet, the volume of chronic inflammatory brain lesions, and
brain volume loss.
South San Francisco, CA — October 8, 2015 —
Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY) today announced data from three positive, pivotal Phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Data from two identical studies (called OPERA I and OPERA II) in people with relapsing MS, which affects approximately 85 percent of people with MS at the time of diagnosis, showed ocrelizumab was superior to interferon beta-1a (Rebif®), a well-established MS therapy, in reducing the three major markers of disease activity over the two-year controlled treatment period.
In a separate study (called ORATORIO) in people with PPMS, a form of the disease marked by steadily worsening symptoms and typically without distinct relapses or periods of remission, ocrelizumab significantly reduced the progression of clinical disability sustained for at least 12 weeks (the primary endpoint) and 24 weeks (a secondary endpoint) compared with placebo. Additionally, the study met other secondary endpoints of reducing the time required to walk 25 feet, the volume of chronic inflammatory brain lesions, and brain volume loss.
“The results of these three pivotal trials have the potential to transform the treatment of MS,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Ocrelizumab is the first investigational medicine to significantly reduce disability progression in people with relapsing MS and people with primary progressive MS – a form of MS with no approved treatments. We are eager to work with regulatory authorities to bring this investigational medicine to the MS community as soon as possible.”
“These results redefine our understanding of MS by highlighting the central role of the B cell,” said Stephen Hauser, M.D., chair of the Scientific Steering Committee of the OPERA studies and chair of the Department of Neurology at the University of California San Francisco School of Medicine. “The findings may also encourage the MS community to look more closely at earlier treatment of the disease. Currently, many doctors reserve what are considered highly effective MS medicines until a patient’s disease becomes more advanced. Patients and their doctors need new treatment options that offer the potential for greater efficacy than a standard-of-care interferon with a similar safety profile.”
The entire press release is attached and can also be found
here: http://www.gene.com/media/press-releases/14609/2015-10-08/genentechs-ocrelizumab-first-investigati
here: http://www.gene.com/media/press-releases/14609/2015-10-08/genentechs-ocrelizumab-first-investigati
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews